Tarceva (erlotinib) and Iressa (gefitnib) are both agents targeted against the EGFR pathway. This pathway is involved in cell growth and replication and when mutated or altered, excessive replication of cells can occur. These agents reduce the uncontrolled replication and growth of cancer cells by blocking mutated EGFR pathways.

According to an article published in the Journal of Clinical Oncology, the targeted agent Tarceva may provide anticancer responses for patients with non-small cell lung cancer (NSCLC) who stop responding to Iressa. These drugs are not associated with the side effects of chemotherapy, providing an effective alternative for patients who are not eligible for standard therapy.

A study was done to evaluate the effectiveness of Tarceva among patients who stopped responding to Iressa. The researchers concluded that -- Patients with NSCLC who demonstrate disease control with Iressa and do not have EGFR mutations appear to have benefit from treatment with Tarceva once their cancer progresses following their treatment with Iressa. Patients with recurrent NSCLC may wish to speak with their physician regarding their individual risks and benefits of treatment with Tarceva.

On Tuesday, researchers announced that a three-drug cocktail may help women with HER2-positive breast cancer better than any other drug used on its own. About one quarter of women with breast cancer make up this HER2 category.

Tests on mice revealed using the three drugs along with breast cancer drug tamoxifen helped wipe out tumors altogether. And the tumors did not come back. This is the first time mice were cured of a very aggressive human breast tumor. Incidentally, when a single drug was used, tumors returned within several weeks.

The three wonder drugs used in this study -- all are monoclonal antibodies that precisely target certain aspects of tumors -- are the experimental drug pertuzumab; trastuzumab, also known as Herceptin; and gefitinib, or Iressa.

Published in the Journal of the National Cancer Institute, this study supports the notion that HER2-positive tumors eventually become resistant to one drug and attacking them on several fronts seems to work better.

The lung cancer drug Gefitinib has been taken off shelves in the United States due to ineffectiveness. But it remains effective in some Taiwanese lung cancer patients, according to a study published in the journal Lung Cancer.

The study, conducted by the National Health Research Institutes, involved 65 non-small-cell lung cancer patients and found that more than 50 percent of participants responded to the drug therapy -- while only 10 percent respond in Western studies.

A genetic mutation of the epidermal growth factor receptor (EGFR) was found in most patients who responded to Gefitinib. The mutation is rare in Western countries but much more common in East Asian countries where the mutation increases the likelihood of developing adenocarcinoma.

About 6,800 Taiwanese patients develop non-small-cell lung cancer every year. Of these, 65 percent of cases are adenocarcinoma. Of this group, 57 percent will have the genetic mutation. And roughly half will respond to Gefitinib.